Gastroesophageal RefluxFT-GER-SONCT02837627
Effect of Tube Feeding on Gastroesophageal Reflux in Preterm Infants
An observational study of Gastroesophageal Reflux, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.
Trial summary
Due to several promoting factors, gastro-esophageal reflux (GER) is very frequent in preterm infants. To limit the potentially harmful widespread of pharmacological treatment, a step-wise approach, which firstly undertakes conservative strategies, is currently considered the best choice to manage GER in the preterm… Read more about this study
- Who is it for?
- Ages 1 week to 4 months
- Conditions the study is for
- Gastroesophageal Reflux
- What is being tested?
- Tube feeding
- How many people
- 31 participants
- Where
- 2 sitesItaly
- Study dates
- 1 Jan 2016to 28 Feb 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 week to 4 months
- All sexes
- No healthy volunteers
- Child
Study population: Due to the exploratory nature of this study, at least 30 preterm infants fulfilling the inclusion criteria will be enrolled.
Who may be able to join
- Preterm newborns (≤ 33 weeks gestation), able to tolerate at least 100 ml kg-1 day-1 of fortified human milk or standard preterm formula, affected by severe/moderate GER symptoms (recurrent regurgitations, feeding difficulties, failure to thrive and/or post-prandial desaturations), whose usual treatment includes a 24-h pH-MII diagnostic evaluation.
- Need for tube feeding at the time of pH-MII
- Weight ≥ 1100 g at the time of enrollment
- Obtained written parental consent.
Who cannot join
- Newborns with serious chronic pathology.
- Ongoing pharmacological treatment that could interfere with gastro-enteral motion functions (pro-kinetics) and/or with gastric acidity (H2 antagonists; proton pump inhibitors; sodium alginate).
- Major congenital malformations (e.g. congenital heart diseases, gastrointestinal abnormalities, malformation syndromes).
- Neonatal necrotizing enterocolitis.
- Ongoing infections.
- Patients with severe clinical conditions that can hinder their participation in this trial (e.g. patent ductus arteriosus, intra-ventricular hemorrhage, hemodynamic instability).
- Administration of experimental medication treatments during the previous two weeks.
Trial locations and contacts
2 sites in 1 country.
Italy2 sites
Neonatal Intensive Care Unit of the S.Orsola-Malpighi Hospital
Bologna, 40138
SC Neonatologia e Terapia Intensiva Neonatale, Ospedale dei Bambini "V. Buzzi"
Milan
About this study
Official title: Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants
Due to several promoting factors, gastro-esophageal reflux (GER) is very frequent in preterm infants. To limit the potentially harmful widespread of pharmacological treatment, a step-wise approach, which firstly undertakes conservative strategies, is currently considered the best choice to manage GER in the preterm population. Among the most common conservative strategies, postural measures seem to effectively reduce GER features in symptomatic preterm babies, whereas feed thickening is almost ineffective.
Due to their prematurity, preterm infants <34 weeks gestation are often unable to coordinate sucking, swallowing and breathing, thus requiring a feeding tube to ensure adequate enteral intakes. Continuous feeding and boluses are the most common techniques of enteral tube feeding in Neonatal Intensive Care Units; at present, however, the effects of these techniques on GER features have not been clearly established.
This observational, prospective and explorative study primarily aims to evaluate the effect of different techniques of enteral tube feeding on GER frequency and features in symptomatic preterm infants (gestational age ≤33 weeks) undergoing a diagnostic combined pH and multiple intraluminal impedance (pH-MII) for GER evaluation.
Read the detailed description
Due to several promoting factors related to the physiological immaturity of the gastro-intestinal tract, gastro-esophageal reflux (GER) is a frequent condition among preterm infants.
GER clinical presentation may vary within a wide range of symptoms, being vomiting, regurgitations and cardiorespiratory events the most common in the preterm population.
Combined pH and multiple intraluminal impedance (pH-MII) is currently considered the best choice for GER diagnosis in preterm infants. While pH monitoring is limited to the detection of acid reflux, combined pH-MII effectively identifies both acid and non-acid GER, which is predominant in preterm infants. Moreover, it allows to evaluate the height reached by the refluxate within the esophageal lumen and to distinguish retrograde fluid bolus movements (reflux) from the anterograde ones (swallows).
In the last decade, GER pharmacological treatment has increasingly widespread in Neonatal Intensive Care Units (NICUs). The provision of anti-histamine2 blockers and proton pump inhibitors in the preterm population, however, might lead to such adverse effects as an increased incidence of necrotizing enterocolitis and infections. Hence, to avoid a useless and potentially harmful pharmacological overtreatment, a step-wise approach, firstly promoting conservative strategies, is currently considered the most advisable choice for GER management in symptomatic preterm infants.
Postural and dietary interventions are the most common conservative strategies and their efficacy in improving GER symptoms and features has been largely investigated.
As previously assessed by pH-MII, both prone and left-side positions were more effective than the right-side or supine ones to significantly improve both acid and non-acid GER features.
Feed thickening is widely employed to reduce vomiting and regurgitations in symptomatic term infants; with regard to the preterm population, however, little data is currently available. The efficacy of thickened fortified human milk on preterm infants with GER symptoms has been previously investigated, observing no benefits. Furthermore, standard human milk fortification itself has been shown to increase GER frequency in preterm infants.
With regard to anti-regurgitation (AR) formulas, the effectiveness of a specific AR formula, thickened with amylopectin and specifically tailored for preterm infants' nutritional needs, has been recently evaluated; the tested thickened formula effectively reduced the number of acid GERs, but no difference was observed in the frequency of non-acid GERs and in the mean esophageal acid exposure, which is known to be the main determinant for the development of gastro-esophageal reflux disease (GERD). Thus, according to these data, feed thickening seem to be almost ineffective in improving GER symptoms and features in preterm infants.
Due to their prematurity, preterm infants <34 weeks gestation are unable to coordinate sucking, swallowing and breathing; thus, to ensure adequate enteral intakes, they are usually fed via an intragastric tube. Continuous and bolus feeding are the most common techniques of enteral tube feeding in NICU settings.
The latter is shown to stimulate cyclical surges of gastrointestinal hormones, thus being considered more physiological. It entails the administration of the meal by gravity or through an infusion pump for a total duration of about 10 minutes, after which the feeding tube could be removed. However, the short time elapsing between the tube insertion for bolus administration and its subsequent removal might provoke a vagal response, characterized by bradycardia and temporary reduction of cardiac output. Moreover, the rapid gastric distension following bolus administration could increase the pressure of lower esophageal sphincter (LES), thus contributing to the refluxate of gastric contents into the esophageal lumen.
On the other hand, continuous feeding allows administering enteral feeds over a longer period (e.g. 2 or 3 hours), at a slower flow rate. It has been associated with better absorption of nutrients and faster gastric emptying, thus it may be preferable in case of delayed gastric motility, gastric residuals and abdominal distension. Moreover, its slow rate of infusion prevents a rapid gastric distension; however, this feeding method requires the permanence of the feeding tube through the LES for the whole feeding period, and this could predispose to the occurrence of gastro-esophageal reflux.
The effect of bolus and continuous feeding on cardio-respiratory events, which could represent clinical atypical manifestations of GER, has been recently evaluated, observing a slight but significant increase of apneic episodes during continuous feeding.
A recent systematic review has aimed to evaluate which of these tube-feeding methods could be more suitable in low birth weight infants with GER symptoms; however, current data are scarce and controversial and do not allow to draw any definitive conclusion.
The aim of this study is to evaluate the effect of different enteral tube feeding modalities, such as bolus and continuous feeding, on pH-MII GER features in tube-fed preterm infants ≤33 weeks gestation, undergoing a diagnostic pH-MII evaluation.
Overall, thirty preterm infants ≤33 weeks gestation will be enrolled if suffering from moderate/severe GER symptoms and if a diagnostic 24-hour pH-MII monitoring has been scheduled to evaluate GER features, according to our clinical practice.
During the 24-h pH-MII monitoring, each infant will receive his meals (usually 8) according to the following sequence:
- 1st meal: optional modality (not considered for statistical analysis);
- 2nd meal: continuous feeding over 3 hours;
- 3rd meal: bolus feeding; the feeding tube remains in place for the whole post-prandial period;
- 4th meal: bolus feeding; the feeding tube is removed after feed administration;
- 5th: continuous feeding over 3 hours;
- 6th : bolus feeding; the feeding tube remains in place for the whole post-prandial period;
- 7th: bolus feeding; the feeding tube is removed after feed administration;
- 8th: optional modality (not considered for statistical analysis). Healthcare assistants will inspect the correct application of this sequence.
The pH-MII device in use for this study (Comfortec pH-MII Sandhill Scientific®) is a nasogastric probe with seven rings, composed by six dipolar impedance channels and one antimony electrode responsible for pH detection and placed in the middle of the distal impedance dipole. Due to these characteristics, pH-MII is able to measure the esophageal height reached by refluxate and to identify the direction of esophageal bolus movements, thereby distinguish between a retrograde flow (reflux) and an anti-retrograde flow (swallow).
The distance between the infant's nose and LES will be determined with Strobel's formula: [baby length (cm) x 0.252 + 5)] - 13%. After placement, the probe's position will be radiographically confirmed.
Data from the pH-MII recording will be automatically acquired on a portable Sleuth Sandhill Scientific system and then stored in a personal computer containing a specific software (BioVIEW Analysis Sandhill Scientific, version 5.0.9). Data analysis will be performed by the aforementioned software and confirmed by direct visual evaluation.
Statistical analysis will be performed by SPSS 20 (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA) for Windows. Differences between the different modalities in terms of GER frequency and features will be tested by Friedman test (level of significance: p <0.05).
- Conditions
- Gastroesophageal Reflux
- Being tested
- Tube feeding
- Keywords
- gastroesophageal reflux, tube enteral feeding, preterm infants
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tube feedingOther
During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
What is being measured
The primary outcome is the main question the study is designed to answer.
Increase/reduction in the frequency of pH-MII GERs
changes in the number of acid, non-acid, liquid and gaseous refluxes
Measured: 24 hours
Secondary outcomes (2)
Increase/reduction in the duration of pH-MII GERs
Changes in the duration of GERs recorded
Measured: 24 hours
Increase/reduction in the esophageal height reached by MII GERs
Changes in the height reached by MII GERs
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2016 (estimated)
- Study start1 Jan 2016
- Primary completion28 Feb 2023
- Study completion28 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Gastroesophageal RefluxStudies of the same condition, open and under way.
- More trials run by IRCCS Azienda Ospedaliero-Universitaria di BolognaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Ospedale dei Bambini "V. Buzzi", Milano
- Responsible party
- Principal investigator, Luigi Corvaglia, IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Investigators
- Luigi T Corvaglia, Prof., Principal investigator, Neonatal Intensive Care Unit, S.Orsola-Malpighi University Hospital, Bologna (Italy)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02837627
- Sponsor's protocol ID
- SO-2016-TF
- Acronym
- FT-GER-SO
- Status last verified
- Aug 2023
- First submitted
- 7 Feb 2016
- Last updated
- 14 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Dhillon AS, Ewer AK. Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 2004 Jan;93(1):88-93.
PubMed 14989446van der Pol RJ, Smits MJ, Venmans L, Boluyt N, Benninga MA, Tabbers MM. Diagnostic accuracy of tests in pediatric gastroesophageal reflux disease. J Pediatr. 2013 May;162(5):983-7.e1-4. doi: 10.1016/j.jpeds.2012.10.041. Epub 2012 Dec 7.
PubMed 23219449Wenzl TG, Moroder C, Trachterna M, Thomson M, Silny J, Heimann G, Skopnik H. Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests for gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2002 May;34(5):519-23. doi: 10.1097/00005176-200205000-00009.
PubMed 12050578Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotten CM; National Institute of Child Health and Human Development Neonatal Research Network. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics. 2008 Jan;121(1):22-7. doi: 10.1542/peds.2007-0381.
PubMed 18166553More K, Athalye-Jape G, Rao S, Patole S. Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants. Am J Perinatol. 2013 Nov;30(10):849-56. doi: 10.1055/s-0033-1333671. Epub 2013 Jan 28.
PubMed 23359235Corvaglia L, Ferlini M, Rotatori R, Paoletti V, Alessandroni R, Cocchi G, Faldella G. Starch thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm infants: a crossover study using intraluminal impedance. J Pediatr. 2006 Feb;148(2):265-8. doi: 10.1016/j.jpeds.2005.09.034.
PubMed 16492440Corvaglia L, Rotatori R, Ferlini M, Aceti A, Ancora G, Faldella G. The effect of body positioning on gastroesophageal reflux in premature infants: evaluation by combined impedance and pH monitoring. J Pediatr. 2007 Dec;151(6):591-6, 596.e1. doi: 10.1016/j.jpeds.2007.06.014. Epub 2007 Oct 24.
PubMed 18035136Aceti A, Corvaglia L, Paoletti V, Mariani E, Ancora G, Galletti S, Faldella G. Protein content and fortification of human milk influence gastroesophageal reflux in preterm infants. J Pediatr Gastroenterol Nutr. 2009 Nov;49(5):613-8. doi: 10.1097/MPG.0b013e31819c0ce5.
PubMed 19633575Corvaglia L, Aceti A, Mariani E, Legnani E, Ferlini M, Raffaeli G, Faldella G. Lack of efficacy of a starch-thickened preterm formula on gastro-oesophageal reflux in preterm infants: a pilot study. J Matern Fetal Neonatal Med. 2012 Dec;25(12):2735-8. doi: 10.3109/14767058.2012.704440. Epub 2012 Jul 13.
PubMed 22725606
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants
- ClinicalTrials.gov ID
- NCT02837627
- Acronym / sponsor ID
- FT-GER-SO / SO-2016-TF
- Conditions
- Gastroesophageal Reflux
- Keywords
- gastroesophageal reflux, tube enteral feeding, preterm infants
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity, hospital or other
- Collaborators
- Ospedale dei Bambini "V. Buzzi", Milano
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 28 Feb 2023 (actual)
- Study completion
- 28 Feb 2023 (actual)
- First posted
- 19 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Due to several promoting factors, gastro-esophageal reflux (GER) is very frequent in preterm infants. To limit the potentially harmful widespread of pharmacological treatment, a step-wise approach, which firstly undertakes conservative strategies, is currently considered the best choice to manage GER in the preterm population. Among the most common conservative strategies, postural measures seem to effectively reduce GER features in symptomatic preterm babies, whereas feed thickening is almost ineffective.
Due to their prematurity, preterm infants <34 weeks gestation are often unable to coordinate sucking, swallowing and breathing, thus requiring a feeding tube to ensure adequate enteral intakes. Continuous feeding and boluses are the most common techniques of enteral tube feeding in Neonatal Intensive Care Units; at present, however, the effects of these techniques on GER features have not been clearly established.
This observational, prospective and explorative study primarily aims to evaluate the effect of different techniques of enteral tube feeding on GER frequency and features in symptomatic preterm infants (gestational age ≤33 weeks) undergoing a diagnostic combined pH and multiple intraluminal impedance (pH-MII) for GER evaluation.
Detailed description
Due to several promoting factors related to the physiological immaturity of the gastro-intestinal tract, gastro-esophageal reflux (GER) is a frequent condition among preterm infants.
GER clinical presentation may vary within a wide range of symptoms, being vomiting, regurgitations and cardiorespiratory events the most common in the preterm population.
Combined pH and multiple intraluminal impedance (pH-MII) is currently considered the best choice for GER diagnosis in preterm infants. While pH monitoring is limited to the detection of acid reflux, combined pH-MII effectively identifies both acid and non-acid GER, which is predominant in preterm infants. Moreover, it allows to evaluate the height reached by the refluxate within the esophageal lumen and to distinguish retrograde fluid bolus movements (reflux) from the anterograde ones (swallows).
In the last decade, GER pharmacological treatment has increasingly widespread in Neonatal Intensive Care Units (NICUs). The provision of anti-histamine2 blockers and proton pump inhibitors in the preterm population, however, might lead to such adverse effects as an increased incidence of necrotizing enterocolitis and infections. Hence, to avoid a useless and potentially harmful pharmacological overtreatment, a step-wise approach, firstly promoting conservative strategies, is currently considered the most advisable choice for GER management in symptomatic preterm infants.
Postural and dietary interventions are the most common conservative strategies and their efficacy in improving GER symptoms and features has been largely investigated.
As previously assessed by pH-MII, both prone and left-side positions were more effective than the right-side or supine ones to significantly improve both acid and non-acid GER features.
Feed thickening is widely employed to reduce vomiting and regurgitations in symptomatic term infants; with regard to the preterm population, however, little data is currently available. The efficacy of thickened fortified human milk on preterm infants with GER symptoms has been previously investigated, observing no benefits. Furthermore, standard human milk fortification itself has been shown to increase GER frequency in preterm infants.
With regard to anti-regurgitation (AR) formulas, the effectiveness of a specific AR formula, thickened with amylopectin and specifically tailored for preterm infants' nutritional needs, has been recently evaluated; the tested thickened formula effectively reduced the number of acid GERs, but no difference was observed in the frequency of non-acid GERs and in the mean esophageal acid exposure, which is known to be the main determinant for the development of gastro-esophageal reflux disease (GERD). Thus, according to these data, feed thickening seem to be almost ineffective in improving GER symptoms and features in preterm infants.
Due to their prematurity, preterm infants <34 weeks gestation are unable to coordinate sucking, swallowing and breathing; thus, to ensure adequate enteral intakes, they are usually fed via an intragastric tube. Continuous and bolus feeding are the most common techniques of enteral tube feeding in NICU settings.
The latter is shown to stimulate cyclical surges of gastrointestinal hormones, thus being considered more physiological. It entails the administration of the meal by gravity or through an infusion pump for a total duration of about 10 minutes, after which the feeding tube could be removed. However, the short time elapsing between the tube insertion for bolus administration and its subsequent removal might provoke a vagal response, characterized by bradycardia and temporary reduction of cardiac output. Moreover, the rapid gastric distension following bolus administration could increase the pressure of lower esophageal sphincter (LES), thus contributing to the refluxate of gastric contents into the esophageal lumen.
On the other hand, continuous feeding allows administering enteral feeds over a longer period (e.g. 2 or 3 hours), at a slower flow rate. It has been associated with better absorption of nutrients and faster gastric emptying, thus it may be preferable in case of delayed gastric motility, gastric residuals and abdominal distension. Moreover, its slow rate of infusion prevents a rapid gastric distension; however, this feeding method requires the permanence of the feeding tube through the LES for the whole feeding period, and this could predispose to the occurrence of gastro-esophageal reflux.
The effect of bolus and continuous feeding on cardio-respiratory events, which could represent clinical atypical manifestations of GER, has been recently evaluated, observing a slight but significant increase of apneic episodes during continuous feeding.
A recent systematic review has aimed to evaluate which of these tube-feeding methods could be more suitable in low birth weight infants with GER symptoms; however, current data are scarce and controversial and do not allow to draw any definitive conclusion.
The aim of this study is to evaluate the effect of different enteral tube feeding modalities, such as bolus and continuous feeding, on pH-MII GER features in tube-fed preterm infants ≤33 weeks gestation, undergoing a diagnostic pH-MII evaluation.
Overall, thirty preterm infants ≤33 weeks gestation will be enrolled if suffering from moderate/severe GER symptoms and if a diagnostic 24-hour pH-MII monitoring has been scheduled to evaluate GER features, according to our clinical practice.
During the 24-h pH-MII monitoring, each infant will receive his meals (usually 8) according to the following sequence:
- 1st meal: optional modality (not considered for statistical analysis);
- 2nd meal: continuous feeding over 3 hours;
- 3rd meal: bolus feeding; the feeding tube remains in place for the whole post-prandial period;
- 4th meal: bolus feeding; the feeding tube is removed after feed administration;
- 5th: continuous feeding over 3 hours;
- 6th : bolus feeding; the feeding tube remains in place for the whole post-prandial period;
- 7th: bolus feeding; the feeding tube is removed after feed administration;
- 8th: optional modality (not considered for statistical analysis). Healthcare assistants will inspect the correct application of this sequence.
The pH-MII device in use for this study (Comfortec pH-MII Sandhill Scientific®) is a nasogastric probe with seven rings, composed by six dipolar impedance channels and one antimony electrode responsible for pH detection and placed in the middle of the distal impedance dipole. Due to these characteristics, pH-MII is able to measure the esophageal height reached by refluxate and to identify the direction of esophageal bolus movements, thereby distinguish between a retrograde flow (reflux) and an anti-retrograde flow (swallow).
The distance between the infant's nose and LES will be determined with Strobel's formula: [baby length (cm) x 0.252 + 5)] - 13%. After placement, the probe's position will be radiographically confirmed.
Data from the pH-MII recording will be automatically acquired on a portable Sleuth Sandhill Scientific system and then stored in a personal computer containing a specific software (BioVIEW Analysis Sandhill Scientific, version 5.0.9). Data analysis will be performed by the aforementioned software and confirmed by direct visual evaluation.
Statistical analysis will be performed by SPSS 20 (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL, USA) for Windows. Differences between the different modalities in terms of GER frequency and features will be tested by Friedman test (level of significance: p <0.05).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 1 week to 4 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Due to the exploratory nature of this study, at least 30 preterm infants fulfilling the inclusion criteria will be enrolled.
Key inclusion criteria (4 listed)
- Preterm newborns (≤ 33 weeks gestation), able to tolerate at least 100 ml kg-1 day-1 of fortified human milk or standard preterm formula, affected by severe/moderate GER symptoms (recurrent regurgitations, feeding difficulties, failure to thrive and/or post-prandial desaturations), whose usual treatment includes a 24-h pH-MII diagnostic evaluation.
- Need for tube feeding at the time of pH-MII
- Weight ≥ 1100 g at the time of enrollment
- Obtained written parental consent.
Key exclusion criteria (7 listed)
- Newborns with serious chronic pathology.
- Ongoing pharmacological treatment that could interfere with gastro-enteral motion functions (pro-kinetics) and/or with gastric acidity (H2 antagonists; proton pump inhibitors; sodium alginate).
- Major congenital malformations (e.g. congenital heart diseases, gastrointestinal abnormalities, malformation syndromes).
- Neonatal necrotizing enterocolitis.
- Ongoing infections.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tube feedingDuring the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period. | Other | – |
Primary outcome
Increase/reduction in the frequency of pH-MII GERs
Time frame: 24 hours
changes in the number of acid, non-acid, liquid and gaseous refluxes
2 secondary outcomes
Increase/reduction in the duration of pH-MII GERs
Time frame: 24 hours
Increase/reduction in the esophageal height reached by MII GERs
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2023.
- Results publication: PubMed 14989446Dhillon AS, Ewer AK. Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 2004 Jan;93(1):88-93.
- Results publication: PubMed 23219449van der Pol RJ, Smits MJ, Venmans L, Boluyt N, Benninga MA, Tabbers MM. Diagnostic accuracy of tests in pediatric gastroesophageal reflux disease. J Pediatr. 2013 May;162(5):983-7.e1-4. doi: 10.1016/j.jpeds.2012.10.041. Epub 2012 Dec 7.
- Results publication: PubMed 12050578Wenzl TG, Moroder C, Trachterna M, Thomson M, Silny J, Heimann G, Skopnik H. Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests for gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2002 May;34(5):519-23. doi: 10.1097/00005176-200205000-00009.
- Results publication: PubMed 18166553Malcolm WF, Gantz M, Martin RJ, Goldstein RF, Goldberg RN, Cotten CM; National Institute of Child Health and Human Development Neonatal Research Network. Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics. 2008 Jan;121(1):22-7. doi: 10.1542/peds.2007-0381.
- Results publication: PubMed 23359235More K, Athalye-Jape G, Rao S, Patole S. Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants. Am J Perinatol. 2013 Nov;30(10):849-56. doi: 10.1055/s-0033-1333671. Epub 2013 Jan 28.
- Results publication: PubMed 16492440Corvaglia L, Ferlini M, Rotatori R, Paoletti V, Alessandroni R, Cocchi G, Faldella G. Starch thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm infants: a crossover study using intraluminal impedance. J Pediatr. 2006 Feb;148(2):265-8. doi: 10.1016/j.jpeds.2005.09.034.
- Results publication: PubMed 18035136Corvaglia L, Rotatori R, Ferlini M, Aceti A, Ancora G, Faldella G. The effect of body positioning on gastroesophageal reflux in premature infants: evaluation by combined impedance and pH monitoring. J Pediatr. 2007 Dec;151(6):591-6, 596.e1. doi: 10.1016/j.jpeds.2007.06.014. Epub 2007 Oct 24.
- Results publication: PubMed 19633575Aceti A, Corvaglia L, Paoletti V, Mariani E, Ancora G, Galletti S, Faldella G. Protein content and fortification of human milk influence gastroesophageal reflux in preterm infants. J Pediatr Gastroenterol Nutr. 2009 Nov;49(5):613-8. doi: 10.1097/MPG.0b013e31819c0ce5.
- Results publication: PubMed 22725606Corvaglia L, Aceti A, Mariani E, Legnani E, Ferlini M, Raffaeli G, Faldella G. Lack of efficacy of a starch-thickened preterm formula on gastro-oesophageal reflux in preterm infants: a pilot study. J Matern Fetal Neonatal Med. 2012 Dec;25(12):2735-8. doi: 10.3109/14767058.2012.704440. Epub 2012 Jul 13.
- Individual participant dataSharing planned: Undecided
Related trials for Gastroesophageal Reflux
RecruitingObservational study
A Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD)
Active, not recruitingObservational study
RETHINK REFLUX Registry
Gastroesophageal Reflux
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
Paraesophageal Hernia, GERD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luigi T Corvaglia, Prof. principal investigator
Neonatal Intensive Care Unit, S.Orsola-Malpighi University Hospital, Bologna (Italy)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastroesophageal Reflux, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increase/reduction in the frequency of pH-MII GERs (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02837627, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2023.